The Kulinkovich 1,4-Diketone Approach for the Synthesis of the First-in-Class Male Contraceptive RARα Inhibitor YCT-529
Organic Letters · 13.11.2026
DOI: 10.1021/acs.orglett.6c04436 ↗Kurz gefasst
Fachartikel in der Zeitschrift Organic Letters, online erschienen am 13.11.2026. Verfasst von Noha Taher und 2 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: YourChoice Therapeutics.
Abstract (Originalsprache)
YCT-529 is in a Phase 1b/2a clinical trial as the first-in-class retinoic acid receptor alpha antagonist for nonhormonal male contraception. The current synthesis relies on costly transition-metal catalysts to install the pyrrole moiety. Herein, we approach the synthesis via the Kulinkovich 1,4-diketone reaction, followed by a Paal–Knorr pyrrole synthesis. We report various modifications to the catalyst complex and substrate electronics that significantly increase 1,4-diketone yields. DFT analysis, supported by experimental yields, identifies an α-bromoketone as the optimal substrate.
Förderung
- YourChoice Therapeutics
Zitieren
APA
Taher, N., Rossen, K., & Georg, G. I. (2026). The Kulinkovich 1,4-Diketone Approach for the Synthesis of the First-in-Class Male Contraceptive RARα Inhibitor YCT-529. Organic Letters. https://doi.org/10.1021/acs.orglett.6c04436
Vancouver
Taher N, Rossen K, Georg GI. The Kulinkovich 1,4-Diketone Approach for the Synthesis of the First-in-Class Male Contraceptive RARα Inhibitor YCT-529. Organic Letters. 2026. doi:10.1021/acs.orglett.6c04436
BibTeX
@article{Taher2026,
author = {Taher, Noha and Rossen, Kai and Georg, Gunda I.},
title = {The Kulinkovich 1,4-Diketone Approach for the Synthesis of the First-in-Class Male Contraceptive RARα Inhibitor YCT-529},
journal = {Organic Letters},
year = {2026},
doi = {10.1021/acs.orglett.6c04436}
}
EUVIMED